DelveInsight’s, “Myelofibrosis Pipeline Insight, 2023,” report provides comprehensive insights about 45+ companies and 45+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including Myelofibrosis clinical trials and nonclinical stage products. It also covers the Myelofibrosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Myelofibrosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Myelofibrosis clinical trials studies, Myelofibrosis NDA approvals (if any), and product development activities comprising the technology, Myelofibrosis collaborations, licensing, Myelofibrosis mergers and acquisition, funding, designations and other product-related details.

 

Key takeaways from the Myelofibrosis Pipeline Report

 

• Over 45+ Myelofibrosis companies are evaluating 45+ Myelofibrosis pipeline therapies in various stages of development, and their anticipated acceptance in the Myelofibrosis market would significantly increase market revenue.

 

• The leading Myelofibrosis Companies includes Pharmaxis, Keros Therapeutics, Bristol-Myers Squibb, Ascentage Pharma Group Inc., Sumitomo Pharma Oncology, Galecto Biotech AB, Actuate Therapeutics Inc, Karyopharm Therapeutics Inc, AbbVie, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Taiga Biotechnologies, Inc., Rigel Pharmaceuticals, Celgene, Novartis Pharmaceuticals, Sierra Oncology, Inc., Incyte Corporation, Imago BioSciences, Inc., Samus Therapeutics, Inc., Constellation Pharmaceuticals, Kartos Therapeutics, Inc., NS Pharma, Inc., Nippon Shinyaku Co., Ltd., Geron Corporation, Inc., Suzhou Zelgen Biopharmaceuticals Co.,Ltd, Hoffmann-La Roche, Lynk Pharmaceuticals Co., Ltd, Chengdu Zenitar Biomedical Technology Co., Ltd, Prelude Therapeutics, Cellenkos, Jacobio Pharmaceuticals, Active Biotech, The Menarini Group,  Cyclica Inc, GAT Therapeutics, Hinova pharmaceuticals, iOnctura,  Telios Pharma, Inc. and many others.

 

• Promising Myelofibrosis Pipeline Therapies includes PXS-5505, KER-050, BMS-986158, APG-1252, TP-3654, GB2064, 9-ING-41, Selinexor, TL-895, Mivebresib, Navitoclax, ABBV-744, Navitoclax, TQ05105, TBX-2400, Fostamatinib, ACE-536, Panobinostat, Momelotinib, Itacitinib, Parsaclisib, Bomedemstat, PU-H71, Pelabresib, KRT-232, NS-018, Imetelstat, TL-895, Jaktinib, Pomalidomide, MMB, RO7490677, INCB057643, LNK01002, INCB000928, LDE225, Flonoltinib, PRT543, CK0804, JAB-8263, Tasquinimod,  and others.

 

• The Myelofibrosis companies and academics are working to assess challenges and seek opportunities that could influence Myelofibrosis R&D. The Myelofibrosis pipeline therapies under development are focused on novel approaches to treat/improve Myelofibrosis.

 

To explore more information on the latest breakthroughs in the Myelofibrosis Pipeline treatment landscape of the report, click here @ Myelofibrosis Pipeline Outlook

 

Myelofibrosis Overview

Myelofibrosis is a rare disorder in which abnormal blood cells and fibers build up in the bone marrow. It is considered as a form of chronic leukemia. When myelofibrosis occurs on its own, it is called as primary myelofibrosis. If the disease occur as the result of a separate disease, it is known as secondary myelofibrosis. One characteristic of myelofibrosis is the overproduction of giant cells called megakaryocytes. Risk factors for myelofibrosis include exposure to ionizing radiation or to petrochemicals, such as benzene or toluene. The diagnosis of myelofibrosis include physical examination, blood tests, imaging tests, bone marrow examination, and gene tests to look for gene mutations in blood cells that are associated with myelofibrosis. Myelofibrosis treatment usually depends on the types of symptoms. Jakafi (ruxolitinib) is the first drug approved by the Food and Drug Administration for the treatment of intermediate or high-risk myelofibrosis.

 

Latest Developmental Activities or News in the Myelofibrosis Treatment Landscape

• In June 2022, Cellenkos announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase Ib, open-label study of CK0804 as an add-on therapy to ruxolitinib in patients with myelofibrosis who experience a suboptimal response to ruxolitinib.
• In June 2022, announced the US FDA granted Orphan Drug Designation for TP-3654, Sumitomo Pharma Oncology’s proprietary investigational oral inhibitor of PIM kinases, for the treatment of myelofibrosis.
• In June 2022, Imago Biosciences presented updated positive data from its ongoing global Phase II clinical study evaluating bomedemstat in patients with advanced myelofibrosis. Bomedemstat was generally safe and well-tolerated in patients with myelofibrosis. The most common non-hematologic adverse event (AE) related to bomedemstat was dysgeusia (altered taste), which occurred in 36% of patients, and dysgeusia led to discontinuation in 1 patient. There were 14 serious adverse events (SAEs) deemed related to bomedemstat per the Investigator.
• In May 2022, Active Biotech announced that US FDA has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis.
• In June 2022, AbbVie announced new data from Cohort 3 of its Phase II REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor naïve patients with myelofibrosis (MF), a rare and difficult to treat blood cancer. These data reinforced the importance of early intervention in myelofibrosis and the potential to achieve improved clinical outcomes.
• In February 2022, Active Biotech entered into an exclusive license agreement with Oncode Institute in the Netherlands, for the global rights to patents relating to the use of tasquinimod and other inhibitors of S100 for use in the treatment of myelofibrosis.
• In April 2022, GlaxoSmithKline has announced the agreed $1.9bn acquisition of biopharmaceutical company Sierra Oncology, which specializes in treatments for rare forms of cancer. This news comes in the wake of Sierra Oncology’s positive top-line results from the MOMENTUM phase III trial earlier this year. This treatment represents a strong asset to complement GSK’s existing hematology portfolio.

 

For further information, refer to the detailed Myelofibrosis Unmet Needs, Myelofibrosis Market Drivers, and Myelofibrosis Market Barriers, click here for Myelofibrosis Ongoing Clinical Trial Analysis

 

Myelofibrosis Emerging Drugs Profile

 

Parsaclisib: Incyte Corporation

Parsaclisib is a potent, highly selective, next-generation investigational novel oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ). The drug is in Phase III clinical evaluation in combination with Ruxolitinib for the treatment of myelofibrosis.

 

KER-050: Keros Therapeutics

KER-050 is an engineered ligand trap comprised of a modified ligand-binding domain of the TGF-β receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain. KER-050 is designed to increase red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-β family of proteins to promote hematopoiesis. It is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. The drug is in Phase II clinical studies for the treatment of Myelofibrosis.

 

Myelofibrosis Pipeline Therapeutics Assessment

There are approx. 45+ key companies which are developing the therapies for Myelofibrosis. The companies which have their Myelofibrosis drug candidates in the most advanced stage, i.e. Phase III include, Incyte Corporation.

 

Request a sample and discover the recent advances in Myelofibrosis Ongoing Clinical Trial Analysis and Medications, click here @ Myelofibrosis Treatment Landscape

 

Scope of the Myelofibrosis Pipeline Insight Report

 

• Coverage- Global
• MyelofibrosisCompanies- Pharmaxis, Keros Therapeutics, Bristol-Myers Squibb, Ascentage Pharma Group Inc., Sumitomo Pharma Oncology, Galecto Biotech AB, Actuate Therapeutics Inc, Karyopharm Therapeutics Inc, AbbVie, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Taiga Biotechnologies, Inc., Rigel Pharmaceuticals, Celgene, Novartis Pharmaceuticals, Sierra Oncology, Inc., Incyte Corporation, Imago BioSciences, Inc., Samus Therapeutics, Inc., Constellation Pharmaceuticals, Kartos Therapeutics, Inc., NS Pharma, Inc., Nippon Shinyaku Co., Ltd., Geron Corporation, Inc., Suzhou Zelgen Biopharmaceuticals Co.,Ltd, Hoffmann-La Roche, Lynk Pharmaceuticals Co., Ltd, Chengdu Zenitar Biomedical Technology Co., Ltd, Prelude Therapeutics, Cellenkos, Jacobio Pharmaceuticals, Active Biotech, The Menarini Group,  Cyclica Inc, GAT Therapeutics, Hinova pharmaceuticals, iOnctura,  Telios Pharma, Inc. and many others.
• Myelofibrosis Pipeline Therapies- PXS-5505, KER-050, BMS-986158, APG-1252, TP-3654, GB2064, 9-ING-41, Selinexor, TL-895, Mivebresib, Navitoclax, ABBV-744, Navitoclax, TQ05105, TBX-2400, Fostamatinib, ACE-536, Panobinostat, Momelotinib, Itacitinib, Parsaclisib, Bomedemstat, PU-H71, Pelabresib, KRT-232, NS-018, Imetelstat, TL-895, Jaktinib, Pomalidomide, MMB, RO7490677, INCB057643, LNK01002, INCB000928, LDE225, Flonoltinib, PRT543, CK0804, JAB-8263, Tasquinimod,  and others.
• Myelofibrosis Pipeline Segmentation: Phases, Mechanism of Action, Route of Administration, Product Type

 

Dive deep into rich insights for drugs for Myelofibrosis Market Drivers and Myelofibrosis Market Barriers, click here @ Myelofibrosis Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Myelofibrosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Myelofibrosis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Parsaclisib: Incyte Corporation
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. KER-050: Keros Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. PXS-5505: Pharmaxis
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. CK-0804: Cellenkos
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Myelofibrosis Key Companies
21. Myelofibrosis Key Products
22. Myelofibrosis- Unmet Needs
23. Myelofibrosis- Market Drivers and Barriers
24. Myelofibrosis- Future Perspectives and Conclusion
25. Myelofibrosis Analyst Views
26. Appendix

 

Got Queries? Find out the related information on Myelofibrosis Mergers and acquisitions, Myelofibrosis Licensing Activities @ Myelofibrosis Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services